First Participants Dosed in RLS-2202 Phase 1A Clinical Trial
Filed with ASX · · 3 pages · English
Story so far
Earlier from Patrys
- PAB Establishes Clinical Advisory Committee
- Appendix 4E - Preliminary Final Report
- Ethics Approval Secured for Phase 1A Clinical Trial
- Investor Presentation - TechKnow Invest Roadshow
- Appendix 4C - Quarterly - 30 June 2026
Later from Patrys
- Appendix 4G and Corporate Governance Statement
- Annual Report - 30 June 2025
- Appendix 4E Variance Report
- Patrys Completes Cohort 1 Dosing and Follow-Up
- Notification of cessation of securities - PAB
Follow Patrys into a list and get an email when it puts out news.
Follow Patrys